Abstract

agilon health, inc. will report quarterly results on August 05, 2026 Post Market, with investor attention centered on revenue resilience, margin trajectory, and whether adjusted EPS tracks the improving consensus path.

Market Forecast

Consensus for the current quarter points to revenue of 1.45 billion US dollars, a 1.46% year-over-year decline, with adjusted EPS expected at -0.12, an improvement of 95.75% year over year; the EBIT outlook stands at -8.98 million US dollars, reflecting an 85.16% year-over-year improvement. Forecast margins were not disclosed in market estimates, but the path implied by EPS and EBIT suggests a narrowing loss profile versus the prior year period.

Medical services remains the core driver and is expected to define both topline and profit trajectory given its overwhelming revenue mix. Within the portfolio, medical services is also the most promising area by scale, having generated 1.42 billion US dollars last quarter; detailed year-over-year growth for this segment was not disclosed, but its 99.87% contribution to revenue underscores its centrality to the quarter’s results.

Last Quarter Review

agilon health, inc. delivered revenue of 1.42 billion US dollars (-7.33% year over year), a gross profit margin of 4.58%, GAAP net profit attributable to the parent of 48.92 million US dollars for a net profit margin of 3.44%, and adjusted EPS of 1.80 (+140% year over year). Revenue exceeded the quarter’s consensus by 40.49 million US dollars and adjusted EPS beat by 0.86, while EBIT of 4.00 million US dollars improved 118.08% year over year but was below the estimate by 8.28 million US dollars. Medical services contributed 1.42 billion US dollars, or 99.87% of total revenue, with segment-level year-over-year growth not disclosed; the concentration emphasizes where operating execution most influences consolidated results.

Current Quarter Outlook

Main business

The medical services business is expected to remain the linchpin of the quarterly print, both for revenue stability and for the earnings path that consensus now expects to improve substantially on a year-over-year basis. With the line-of-sight to 1.45 billion US dollars of revenue and a 95.75% year-over-year improvement in adjusted EPS implied by estimates, investors will parse whether unit economics and medical cost performance are tracking favorably versus the same period last year. The revenue decline of 1.46% year over year suggests a relatively stable topline backdrop compared with last quarter’s -7.33% year-over-year contraction, which places additional emphasis on cost discipline, claims development, and contract-level profitability to support the improved EPS trajectory. Operationally, durable improvement in medical cost containment and any indications that claim run-rate or utilization patterns are normalizing versus last year would be supportive of the implied EBIT improvement to -8.98 million US dollars. Attention will also focus on any commentary around growth cadence within existing markets, as the heavy weighting of medical services creates a tight link between execution within that book of business and the quarter’s gross margin outcome. Given the modest gross margin last quarter (4.58%), even small improvements in medical margin can have an outsized effect on EPS, which helps explain the substantial year-over-year improvement expected by consensus despite a near-flat revenue profile. The market will also be sensitive to whether last quarter’s positive surprises on revenue and adjusted EPS reflect a sustainable run-rate or were driven by timing effects that might not recur.

Most promising business

Medical services, by virtue of scale and contribution, remains the most promising area for earnings leverage over the next print. It delivered 1.42 billion US dollars last quarter and comprises 99.87% of revenue, leaving clear potential for small improvements in unit costs, care coordination, and contract performance to create noticeable changes in adjusted EPS. The implied year-over-year improvement in EBIT and EPS for this quarter, despite only a slight revenue decline, points to the possibility that operational initiatives are beginning to accumulate into measurable P&L impact. Any evidence of improved claims predictability, tighter referral patterns, or enhanced documentation and coding consistency can strengthen the medical margin, and thereby help translate near-flat revenue into a better earnings result. Although segment-specific year-over-year growth was not disclosed, the combination of scale and the sensitivity of earnings to medical margin creates a setup in which incremental operational execution within medical services carries the highest upside potential for this quarter’s print. A further positive indication would be confirmation that the steps evident in last quarter’s revenue and adjusted EPS beats are sustainable, not singular events. That continuity would underpin confidence in the expected adjusted EPS improvement and support the notion that profitability can improve even without a large top-line expansion.

Stock-price swing factors this quarter

Relative to the 1.45 billion US dollars revenue consensus, a narrow beat or miss could move the shares because the topline now appears to be stabilizing versus the prior year, making small deviations more meaningful for investor expectations. Adjusted EPS versus the -0.12 estimate will likely be the primary stock driver, especially if margin signals imply further improvement against last year’s baseline; a print close to breakeven would likely be viewed as outsized progress given the current consensus trajectory. The medical services cost profile will be under scrutiny, particularly any indications on claims development, utilization patterns, or benefit-cost trend moderation compared with last year’s pressures, because these directly inform the gross margin and EBIT path. Investors will also parse the mix of mature versus newer cohorts within the medical services book, looking for signs that maturing contracts are generating better economics that can offset areas of pressure. Given last quarter’s revenue and EPS beats, tone around continuity of those drivers will matter; confirmation of ongoing execution would raise confidence that the large year-over-year EPS improvement implied for this quarter is achievable. Finally, any update on operating expense efficiency or scalability may influence the slope of EBIT improvement that consensus embeds, given the small absolute level of EBIT expected this quarter and the high sensitivity of EPS to incremental margin gains.

Analyst Opinions

Bullish opinions are in the majority among the recent updates collected in the coverage window, with a ratio of approximately two bullish to one bearish. Jefferies upgraded agilon health, inc. to Buy and raised its price target (to 48.00 US dollars on a post-split basis), citing improved earnings visibility following the strong last-quarter performance and a better-than-expected adjusted EPS print. Deutsche Bank also upgraded the shares to Buy with a target of 49.00 US dollars, highlighting evidence that operational execution is translating into faster-than-modeled earnings inflection and that the company appears on a credible path to margin normalization. These calls align with the quarter’s setup in which consensus expects only a slight revenue decline year over year yet a near-doubling improvement in adjusted EPS, implying that the core margin narrative rather than top-line acceleration is doing the heavy lifting. The constructive stance reflects confidence that the medical services engine can deliver incremental medical margin gains, which have an outsized effect on consolidated results given the segment’s scale and the company’s low base of operating profit. Some institutions also adjusted targets mechanically to reflect the completed 25-for-1 reverse split, which does not alter the fundamental thesis but keeps published price objectives consistent with the new share count and per-share arithmetic. In aggregate, the bullish camp argues that the last quarter’s revenue and adjusted EPS beats are early confirmation that the business is capable of tighter cost control and more predictable claims development, making the consensus path for a smaller loss this quarter plausible. The majority view is not predicated on rapid revenue acceleration; rather, it is grounded in the improved earnings conversion that is visible in the estimates for adjusted EPS and EBIT. This framing sets a clear bar for the upcoming report: demonstrate continued progress on medical services unit economics and cost execution, and the shares should find support consistent with the prevailing bullish stance.